Aktis Oncology Inc (AKTS)
Aktis Oncology Inc (NASDAQ-AKTS) is a common stock security listed on NASDAQ. The company is in the healthcare sector and biotechnology industry, and the security context is common equity. Aktis Oncology Inc is associated with oncology-focused research activities and the development of cancer-related therapies, with attention on targeted approaches for tumors. As a listed equity, the security reflects ownership in the company rather than a fund, debt instrument, or other structured product. Investors typically use this type of listing to follow the company’s public-market trading and corporate disclosures within the biotechnology space.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AKTS
|
$19.50
|
-21.3% Downside
|
Overvalued
|
$34.38
|
38.8% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-20.4x
|
2.7x
|
165.0x
|
1.324 B
|
838.4 M
|
0.9%
|
50.9%
|
11.5
|
—
|
119.9%
|
